Repligen Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh (R2GE34) Stock Price & Analysis

R2GE34 Stock Chart & Stats

R$31.34R$0.00(0.00%)

At close: Nov 13

Day’s Range: BRL 0.01 - BRL 31.83
52-Week Range: BRL 0.01 - BRL 34.14
Previous Close: BRL 31.34
Volume: N/A
Average Volume (3M): 65
Market Cap: BRL 60.78B
Enterprise Value: BRL 30.58B
Total Cash (Recent Filing): N/A
Total Debt (Recent Filing): N/A
Price to Earnings (P/E): ―
Beta: 0.12
Next Earnings: Feb 24, 2027 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Repligen Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh News

Repligen to issue $1B of 0.25% Convertible Senior Notes due 2031

Repligen (RGEN) announced that it entered into privately negotiated exchange and/or subscription agreements with certain holders of its outstanding 1.00% Convertible Senior Notes due 2028 and certain new investors, pursuant

2w agoRGEN RGN

Repligen price target raised to $200 from $185 at RBC Capital

RBC Capital analyst Dan Leonard raised the firm’s price target on Repligen (RGEN) to $200 from $185 and keeps an Outperform rating on the shares. The company’s Q3 results were

2w agoRGEN RGN

Midday Fly By: Nvidia, AMD invest in Meta offering, Coca-Cola reports

The major averages were higher near noon as investors brace for the Federal Reserve’s interest-rate decision and a busy slate of corporate earnings. The Federal Reserve begins its two-day policy

2w agoBA KO

Repligen reports Q3 adjusted EPS 53c, consensus 46c

Reports Q3 revenue $209.31M, consensus $206.75M. Olivier Loeillot, President and Chief Executive Officer of Repligen (RGEN) said, “We delivered a record third quarter, with $209 million in revenue and 12.5%

2w agoRGEN RGN

Repligen narrows FY26 adjusted EPS view to $2.05-$2.09 from $2.03-$2.09

Consensus $2.06. Raises FY26 revenue view to $844M-$852M from $813M-$835M, consensus $836.29M. Loeillot continued, “The completion of the BioLife acquisition in October marks a significant milestone for Repligen (RGEN), and

2w agoRGEN RGN

Repligen price target raised to $180 from $145 at Canaccord

Canaccord raised the firm’s price target on Repligen (RGEN) to $180 from $145 and keeps a Hold rating on the shares. The firm updated its model ahead of Q3 results.

3w agoRGEN RGN

Private Markets: Varda Space, GMI headline week’s startup fundraising

Funding momentum stayed strong this week as companies in space manufacturing, AI compute, super intelligence platforms and financial tech infrastructure secured some of the largest private raises of the quarter.

1M agoCAT DHR

Repligen price target raised to $225 from $175 at Barclays

Barclays analyst Luke Sergott raised the firm’s price target on Repligen (RGEN) to $225 from $175 and keeps an Overweight rating on the shares. The firm adjusted targets in the

1M agoRGEN RGN

Freshworks to replace BioLife Solutions in S&P 600 at open on 10/8

Repligen (RGEN) is acquiring BioLife Solutions (BLFS) in a deal expected to be completed soon, pending final closing conditions. Published first on TheFly – the ultimate source for real-time, market-moving

1M agoBLFS FRSH

Repligen Buy Rating Reiterated as Analyst Sees Medium-Term Growth Catalysts; Price Target Maintained at $225

Analyst Doug Schenkel from UBS maintained a Buy rating on Repligen and keeping the price target at $225.00. Doug Schenkel has given his Buy rating due to a combination of

1M agoRGEN RGN

Repligen assumed with a Buy at UBS

UBS assumed coverage of Repligen (RGEN) with a Buy rating and $225 price target Repligen is a differentiated pure-play bioprocessing growth story with a path to sustained mid-teens revenue growth

2M agoRGEN RGN

Repligen’s Operational Momentum Offset by Full Valuation; Kyle Mikson CFA Reiterates Hold with Unchanged $145 Price Target

Repligen, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kyle Mikson CFA from Canaccord Genuity maintained a Hold rating on the stock and has a

3M agoRGEN RGN

Repligen Earns Buy Rating on Strong Q2 Beat, Raised Guidance, and Broad-Based Demand Strength

William Blair analyst Matt Larew has maintained their bullish stance on RGEN stock, giving a Buy rating on July 23. Matt Larew has given his Buy rating due to a

3M agoRGEN RGN

Repligen Earns Buy Rating on BioLife Acquisition Synergies and Strong Organic Growth

William Blair analyst Matt Larew has maintained their bullish stance on RGEN stock, giving a Buy rating on July 7. Matt Larew has given his Buy rating due to a

3M agoRGEN RGN

R2GE34 FAQ

What was Repligen Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh’s price range in the past 12 months?

Repligen Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh lowest stock price was R$0.01 and its highest was R$34.14 in the past 12 months.

What is Repligen Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh’s market cap?

Repligen Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh’s market cap is R$60.78B.

When is Repligen Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Repligen Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh’s earnings last quarter?

Repligen Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh released its earnings results on Oct 27, 2026. The company reported R$0 earnings per share for the quarter.

Is Repligen Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Repligen Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh pay dividends?

Repligen Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh does not currently pay dividends.

What is Repligen Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh’s EPS estimate?

Repligen Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Repligen Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh have?

Repligen Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh has 1,917,903,900 shares outstanding.

What happened to Repligen Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh’s price movement after its last earnings report?

Repligen Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh reported an EPS of R$0 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Repligen Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh?

Currently, no hedge funds are holding shares in BR:R2GE34

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Repligen Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh (R2GE34) Earnings & Revenues

Historic Earnings Reports

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	10	1	11
Technical Analysis	4	1	5
Moving Averages	6	0	6

Technical Analysis >

Similar Stocks

Stocks similar to BR:R2GE34
Company	Price & Change	Follow
BR:C1NS34Celanese Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh
BR:C2GN34Cognex Corp Shs Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh
BR:I2NG34Ingredion Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh
BR:P1NR34Pentair PLC Shs Unsponsored Brazilian Depositary Receipt Repr 1 Sh
BR:R1DY34Dr Reddy'S Laboratories Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR

Compare BR:R2GE34 Stocks >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

R2GE34 Stock Chart & Stats

Repligen Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh News

Repligen to issue $1B of 0.25% Convertible Senior Notes due 2031

Repligen price target raised to $200 from $185 at RBC Capital

Midday Fly By: Nvidia, AMD invest in Meta offering, Coca-Cola reports

Repligen reports Q3 adjusted EPS 53c, consensus 46c

Repligen narrows FY26 adjusted EPS view to $2.05-$2.09 from $2.03-$2.09

Repligen price target raised to $180 from $145 at Canaccord

Private Markets: Varda Space, GMI headline week’s startup fundraising

Repligen price target raised to $225 from $175 at Barclays

Freshworks to replace BioLife Solutions in S&P 600 at open on 10/8

Repligen Buy Rating Reiterated as Analyst Sees Medium-Term Growth Catalysts; Price Target Maintained at $225

Repligen assumed with a Buy at UBS

Repligen’s Operational Momentum Offset by Full Valuation; Kyle Mikson CFA Reiterates Hold with Unchanged $145 Price Target

Repligen Earns Buy Rating on Strong Q2 Beat, Raised Guidance, and Broad-Based Demand Strength

Repligen Earns Buy Rating on BioLife Acquisition Synergies and Strong Organic Growth

R2GE34 FAQ

Repligen Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh (R2GE34) Earnings & Revenues

Technical Analysis

Overall Consensus

Similar Stocks

Popular Stocks

Become an Expert with TipRanks Premium